Graypoint LLC Invests $229,000 in Agilent Technologies, Inc. (NYSE:A)

Graypoint LLC acquired a new position in Agilent Technologies, Inc. (NYSE:A) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,543 shares of the medical research company’s stock, valued at approximately $229,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Crewe Advisors LLC boosted its position in shares of Agilent Technologies by 114.8% during the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after acquiring an additional 101 shares during the last quarter. Livelsberger Financial Advisory bought a new position in shares of Agilent Technologies during the third quarter worth $28,000. Ridgewood Investments LLC bought a new position in shares of Agilent Technologies during the second quarter worth $29,000. Fortitude Family Office LLC boosted its position in shares of Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after acquiring an additional 95 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new position in shares of Agilent Technologies during the second quarter worth $39,000.

Insider Buying and Selling

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,995 shares of company stock valued at $1,739,510 in the last 90 days.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on A shares. UBS Group upped their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Evercore ISI increased their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Stifel Nicolaus reiterated a “buy” rating and set a $151.00 price objective on shares of Agilent Technologies in a research report on Monday, August 26th. Wells Fargo & Company started coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price objective for the company. Finally, TD Cowen increased their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $144.36.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $136.68 on Friday. The firm has a 50-day moving average price of $139.46 and a 200-day moving average price of $138.21. The firm has a market capitalization of $39.27 billion, a PE ratio of 28.36, a price-to-earnings-growth ratio of 6.06 and a beta of 1.07. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a 12-month low of $104.09 and a 12-month high of $155.35.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The firm’s revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.43 EPS. As a group, equities research analysts forecast that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were paid a $0.236 dividend. This represents a $0.94 annualized dividend and a yield of 0.69%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio is presently 19.50%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.